Target intelligence / Profile preview

Fibroblast growth factor 1 (FGF1) (FGF1)

Target
FGF1
Molecular classification
Growth factor, Heparin-binding protein
01

Overview

Fibroblast growth factor 1 (FGF1), also known as acidic fibroblast growth factor, is a versatile signaling protein that belongs to the heparin-binding growth factor family (UniProt P05230). It is unique among the FGF family for its ability to bind and activate all four tyrosine kinase FGF receptors (FGFR1, 2, 3, and 4), making it a potent regulator of cell growth, differentiation, and survival (PubMed: 11087100). The heparin-binding domain of FGF1 is a critical structural feature that mediates its interaction with heparan sulfate proteoglycans, which act as essential co-receptors to stabilize the FGF-FGFR complex and trigger intracellular signaling (PubMed: 15591318). In clinical contexts, FGF1 is a target for therapeutic intervention in wound healing and cardiovascular repair due to its pro-angiogenic and mitogenic properties (PubMed: 22403074). Recent research has also identified FGF1 as a potent metabolic regulator, with engineered non-mitogenic variants showing promise in treating type 2 diabetes and nonalcoholic steatohepatitis (NASH) by improving insulin sensitivity without the risk of tumor promotion (PubMed: 25043058).

Other names
Acidic fibroblast growth factoraFGFHeparin-binding growth factor 1HBGF-1FGFABeta-endothelial cell growth factorAcidic fibroblast growth factor heparin-binding domain
02

Mechanism of action

Agonism of fibroblast growth factor receptors (FGFR1-4) facilitated by heparin or heparan sulfate proteoglycans to activate downstream MAPK/ERK and PI3K/Akt signaling pathways (PubMed: 15591318).

03

Biological functions

Cell proliferationAngiogenesisWound healingGlucose homeostasisCell survivalMitogenesis
04

Disease associations

Diabetes mellitusCardiovascular diseaseChronic woundNonalcoholic steatohepatitis (NASH)Cancer
05

Safety considerations

Mitogenic potential and risk of oncogenesisShort biological half-lifePotential for excessive or pathological angiogenesisThermal instability
06

Interacting drugs

Paldermin

3 more in the full profile.

07

Biomarkers

Serum FGF1 levelsFGFR1 expression in adipose tissueBlood glucose levelsInsulin sensitivity markers (e.g., HOMA-IR)

Beyond the preview

Go deeper on Fibroblast growth factor 1 (FGF1) (FGF1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fibroblast growth factor 1 (FGF1) (FGF1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call